Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine

Wang,Kai; Huynh,Nhi; Wang,Xiao; Baldwin,Graham; Nikfarjam,Mehrdad; He,Hong

doi:10.3892/ijo.2017.4193

Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine

Authors:
- Kai Wang
- Nhi Huynh
- Xiao Wang
- Graham Baldwin
- Mehrdad Nikfarjam
- Hong He
View Affiliations

Affiliations: Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria 3048, Australia
Published online on: November 7, 2017 https://doi.org/10.3892/ijo.2017.4193
Pages: 261-269

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic ductal adenocarcinoma (PDA) is one of the major types of cancer that exhibit high mortality worldwide because of the late diagnosis and the lack of effective treatment. Immunotherapy appears to be ineffective in PDA treatment due to the existence of a unique immune-suppressive microenvironment in PDA. Gemcitabine-based therapy is still the most commonly used chemotherapy to treat PDA patients with only marginal increased survival rates. This prompted us to continue the search for more effective therapy for PDA treatment. The effects of p21 activated kinases (PAKs) on tumour immune response and gemcitabine response were examined in PDA. An orthotopic murine PDA model, in which pancreatic cancer cells were injected to the tail of pancreas, was used. The mice were treated with PAK inhibitor, PF‑3758309, plus or minus gemcitabine. Tumour growth was measured by volume and weight. Tumour immune response was determined by flow cytometry analysis of splenic cells and immunohistochemical staining of intratumoural lymphocytes. Inhibition of PAKs by PF‑3758309, not only suppressed tumour growth, but also stimulated tumour immune response by increasing the numbers of splenic and intratumoural T lymphocytes. Furthermore, inhibition of PAKs decreased PDA cell growth synergistically with gemcitabine in vitro and in vivo. The dual effects of inhibition of PAKs make PAK-targeted therapy more potent for the treatment of PDA. The combination of PAK inhibitors with gemcitabine may be a more effective therapeutic approach in PDA treatment.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
3	Zhang Y, Hochster H, Stein S and Lacy J: Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity. Exp Hematol Oncol. 4:292015. View Article : Google Scholar : PubMed/NCBI
4	Sharma P and Allison JP: The future of immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
5	Zheng L, Xue J, Jaffee EM and Habtezion A: Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology. 144:1230–1240. 2013. View Article : Google Scholar : PubMed/NCBI
6	He H and Baldwin GS: p21-activated kinases and gastrointestinal cancer. Biochim Biophys Acta. 1833:33–39. 2013. View Article : Google Scholar
7	Yeo D, He H, Patel O, Lowy AM, Baldwin GS and Nikfarjam M: FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. BMC Cancer. 16:242016. View Article : Google Scholar : PubMed/NCBI
8	Tyagi N, Bhardwaj A, Singh AP, McClellan S, Carter JE and Singh S: p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-κB pathway. Oncotarget. 5:8778–8789. 2014. View Article : Google Scholar : PubMed/NCBI
9	Tyagi N, Marimuthu S, Bhardwaj A, Deshmukh SK, Srivastava SK, Singh AP, McClellan S, Carter JE and Singh S: p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling. Cancer Lett. 370:260–267. 2016. View Article : Google Scholar
10	Moon SU, Kim JW, Sung JH, Kang MH, Kim SH, Chang H, Lee JO, Kim YJ, Lee KW, Kim JH, et al: p21-activated kinase 4 (PAK4) as a predictive marker of gemcitabine sensitivity in pancreatic cancer cell lines. Cancer Res Treat. 47:501–508. 2015. View Article : Google Scholar : PubMed/NCBI
11	Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, et al Australian Pancreatic Cancer Genome Initiative: Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 491:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
12	Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J, Dagostino E, Knighton D, Loi CM, Zager M, et al: Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci USA. 107:9446–9451. 2010. View Article : Google Scholar : PubMed/NCBI
13	Huynh N, Liu KH, Baldwin GS and He H: p21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways. Biochim Biophys Acta. 1803:1106–1113. 2010. View Article : Google Scholar : PubMed/NCBI
14	Yeo D, Huynh N, Beutler JA, Christophi C, Shulkes A, Baldwin GS, Nikfarjam M and He H: Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases. Cancer Lett. 346:264–272. 2014. View Article : Google Scholar : PubMed/NCBI
15	Bang D, Wilson W, Ryan M, Yeh JJ and Baldwin AS: GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB. Cancer Discov. 3:690–703. 2013. View Article : Google Scholar : PubMed/NCBI
16	Nikfarjam M, Yeo D, He H, Baldwin G, Fifis T, Costa P, Tan B, Yang E, Wen Sw and Christophi C: Comparison of two syngeneic orthotopic murine models of pancreatic adenocarcinoma. J Invest Surg. 26:352–359. 2013. View Article : Google Scholar : PubMed/NCBI
17	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
18	Newman AM and Alizadeh AA: High-throughput genomic profiling of tumor-infiltrating leukocytes. Curr Opin Immunol. 41:77–84. 2016. View Article : Google Scholar : PubMed/NCBI
19	Junttila MR and de Sauvage FJ: Influence of tumour microenvironment heterogeneity on therapeutic response. Nature. 501:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
20	Rooney MS, Shukla SA, Wu CJ, Getz G and Hacohen N: Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 160:48–61. 2015. View Article : Google Scholar : PubMed/NCBI
21	Peske JD, Woods AB and Engelhard VH: Control of CD8 T-cell infiltration into tumors by vasculature and microenvironment. Adv Cancer Res. 128:263–307. 2015. View Article : Google Scholar : PubMed/NCBI
22	Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, et al: Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 73:3499–3510. 2013. View Article : Google Scholar : PubMed/NCBI
23	Sideras K, Braat H, Kwekkeboom J, van Eijck CH, Peppelenbosch MP, Sleijfer S and Bruno M: Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev. 40:513–522. 2014. View Article : Google Scholar
24	Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y and Hiraoka N: Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 108:914–923. 2013. View Article : Google Scholar : PubMed/NCBI
25	Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawaradaz Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, et al: CD8⁺ tumor-infiltrating lymphocytes together with CD4⁺ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 28:e26–e31. 2004. View Article : Google Scholar : PubMed/NCBI
26	Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S and Tuveson DA: Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 7:469–483. 2005. View Article : Google Scholar : PubMed/NCBI
27	Eriksson E, Wenthe J, Irenaeus S, Loskog A and Ullenhag G: Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. J Transl Med. 14:2822016. View Article : Google Scholar
28	Shibuya KC, Goel VK, Xiong W, Sham JG, Pollack SM, Leahy AM, Whiting SH, Yeh MM, Yee C, Riddell SR, et al: Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One. 9:e965652014. View Article : Google Scholar : PubMed/NCBI
29	Manji GA, Olive KP, Saenger YM and Oberstein P: Current and emerging therapies in metastatic pancreatic cancer. Clin Cancer Res. 23:1670–1678. 2017. View Article : Google Scholar : PubMed/NCBI
30	Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 28:3605–3610. 2010. View Article : Google Scholar : PubMed/NCBI
31	Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, et al: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 28:3617–3622. 2010. View Article : Google Scholar : PubMed/NCBI